The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Altimmune (NASDAQ:ALT) lost ~64% in the premarket on Thursday after the company announced a mixed readout from a mid-stage trial for pemvidutide, its experimental therapy for a liver condition known ...
In my last note on Altimmune, Inc. (ALT) shared in late August, I made the bull case for its stock. I discussed the Gaithersburg, Maryland based biotech's lead and only drug candidate, pemvidutide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results